Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $15.06, but opened at $15.91. Ascentage Pharma Group International shares last traded at $15.98, with a volume of 6,704 shares.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on AAPG shares. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $46.43.
Get Our Latest Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Price Performance
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million for the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.
The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.
Recommended Stories
- Five stocks we like better than Ascentage Pharma Group International
- 3 Overlooked Tech Names Quietly Powering Everyday Life
- 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street Support
- These 3 AI Stocks Sold Off Hard—Even as Their Outlooks Improved
- Think Outside the Box With These 3 Companies That Make Unusual Business Models Work
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
